70558-11-1

Basic information

• Product Name: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE
• Synonyms: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE;6-Chloro-3,4-dihydro-2H-benzo[1,4]oxazine;6-Chloro-3,4-dihydro-2H-1,4-benzoxazine;6-Chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine;6-Chloro-3,4-dihydro-2H-benzo[1,4]oxazine 1HCl salt
• CAS NO: 70558-11-1
• Molecular Formula: C₈H₈ClNO
• Molecular Weight: 169.61
• Mol File: 70558-11-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 33-34 °C(Solv: cyclohexane (110-82-7))
• Boiling Point: 104-106 °C(Press: 0.004 Torr)
• Appearance: /
• Density: 1.253±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.63±0.20(Predicted)
• CAS DataBase Reference: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE(70558-11-1)
• EPA Substance Registry System: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE(70558-11-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 70558-11-1(Hazardous Substances Data)

Usage

General Description

6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE is a chemical compound with the molecular formula C8H8ClNO. It is a hydrochloride salt of a benzooxazine derivative, and it is commonly used in pharmaceutical research and development. 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE has potential biological activity and is being investigated for its potential therapeutic applications. It is also used as a building block for the synthesis of various pharmaceutical compounds. However, its specific properties and potential uses are still being explored through ongoing research and studies.

Upstream product

• 95-85-2 2-hydroxy-5-chloro-aniline 
• 35588-38-6 2-chloro-N-(5-chloro-2-hydroxyphenyl)acetamide 
• 247129-85-7 (2-bromoethyl)(diphenyl)sulfonium trifluoromethanesulfonate 
• 7652-29-1 6-chloro-2H-1,4-benzoxazin-3(4H)-one 
• 79-04-9 chloroacetyl chloride 
• 106-93-4 ethylene dibromide 

Relevant articles and documents

Design, synthesis, and bioevaluation of substituted phenyl isoxazole analogues as herbicide safeners

Herbicide safeners enhance herbicide detoxification in crops without affecting target weed sensitivity. To enhance crop tolerance to the toxicity-related stress caused by the herbicide acetochlor (ACT), a new class of substituted phenyl isoxazole derivatives was designed by an intermediate derivatization method as herbicide safeners. Microwave-assisted synthesis was used to prepare the phenyl isoxazole analogues, and all of the structures were confirmed via IR, 1H NMR, 13C NMR, and HRMS. Compound I-1 was further characterized by X-ray diffraction analysis. Bioassay results showed that most of the obtained compounds provided varying degrees of safening against ACT-induced injury by increasing the corn growth recovery, glutathione content, and glutathione S-transferase activity. In particular, compound I-20 showed excellent safener activity against ACT toxicity, comparable to that of the commercial safener benoxacor. Gaussian calculations have been performed and the results indicated that the nucleophilic ability of compound I-20 is higher than that of benoxacor, thus the activity is higher than that of benoxacor. These findings demonstrate that phenyl isoxazole derivatives possess great potential for protective management in cornfields.

Simple and efficient synthesis of novel N -dichloroacetyl-3,4-dihydro-2 H -1,4-benzoxazines

An easy synthetic route to N -dichloroacetyl- 3,4-dihydro-2 H -1,4-benzoxazine derivatives 3 involves cyclization of 2-aminophenols 1 with 1,2-dibromoethane and subsequent acylation of the resultant 3,4-dihydro- 2 H -1,4-benzoxazine derivatives 2 with dichloroacetyl chloride. All compounds were characterized by IR, 1 H NMR, 13 C NMR, ESI-MS and elemental analysis. The structure of 3a was determined by X-ray crystallographic analysis.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.